- Home
- GRPN vs CRVS Comparison
GRPN vs CRVS Comparison
Compare GRPN & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRPN | CRVS |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.4M | 634.0M |
| IPO Year | 2011 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GRPN | CRVS |
|---|---|---|
| Price | $18.17 | $7.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $31.25 | $13.75 |
| AVG Volume (30 Days) | 940.9K | ★ 1.6M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $496,093,000.00 | N/A |
| Revenue This Year | $4.17 | N/A |
| Revenue Next Year | $10.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.21 | $2.54 |
| 52 Week High | $43.08 | $9.60 |
Technical Indicators
Market Signals| Indicator | GRPN | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 44.45 |
| Support Level | $15.50 | $7.34 |
| Resistance Level | $18.68 | $8.00 |
| Average True Range (ATR) | 0.75 | 0.52 |
| MACD | 0.32 | -0.12 |
| Stochastic Oscillator | 81.45 | 18.42 |
Price Performance
Historical ComparisonAbout GRPN Groupon Inc.
Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).